Cosmos Health Inc.

Now live in Oceania: e-commerce subscription business operating across Australia, New Zealand and the broader Oceania region, with sales already underway Attractive markets: together, Australia and New Zealand represent multibillion-dollar, well-established health and wellness markets with strong consumer demand and high e-commerce adoption Scalable platform: powered by the same platform behind the Company's growth in the United States Global ambitions: Oceania marks the next step in bringing th…

Key Highlights Record revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record 2026 outlook reaffirmed: full-year revenue expected to surpass $90 million, up approximately 38%, the largest single-year revenue increase in the Company's history Record fourth quarter expected: revenue of approximately $35.7 million or more, up approximately 81% from the fourth quarter of 2025 Multiple engines of growth: pharmaceutical contract …

● Q4 2026 U.S. revenue: approximately $15 million expected, based on the Company's current growth trajectory ● Q4 2026 gross profit: approximately $10.5 million expected, at an approximately 70% gross margin ● Subscription revenue: approximately $11.5 million expected, from approximately $8.2 million in first orders and approximately $3.3 million in renewals ● Order volume: 14,624 online checkout orders tracked as of October 19, 2026, up 34% from the 10,881 announced on October 14, 2026 ● Subscr…

● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company accelerates investment in its U.S. platform ● 60.5% of U.S. online checkout orders included a subscription, rising to more than 75% in recent days as adoption accelerates ● $919,945 monthly subscription value at standard renewal pricing as of October 14, 2026 ● 2.4 product units per subscription on average, with 14,793 units across 12,408 active subscription lines ● 10,881 U.S. on…

Record day: U.S. direct-to-consumer sales exceeded $92,000 on October 11, 2026, the highest single day to date $902,000 in 30 days: approximately $30,000 in average daily sales over the trailing 30-day period Accelerating: average daily sales of more than $60,000 over the past 10 days, double the 30-day average Approaching U.S. target: the 10-day pace, if sustained, corresponds to approximately $21.9 million annualized, nearing the over $23 million in annual U.S. revenue the Company previously p…

Record nine-month revenue of approximately $54.3 million - up 19%, or $8.7 million, from $45.6 million in the same period of 2025 Nine-month 2026 revenue nearly matches the whole of 2024 - when full-year revenue was $54.4 million - and represents 83% of record full-year 2025 revenue of $65.3 million Record third-quarter revenue of approximately $17.4 million - exceeding the previous Q3 record of $17.1 million set in 2025, and up 40% on Q3 2024 Every quarter of 2026 has set a record for its perio…

More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded generics Proprietary brands sold in more than 40 countries - across Europe, the Middle East, North America and Asia, through pharmacies, hospitals, retail chains and e-commerce Addressable markets of approximately $946 billion - the six product categories and two service markets in which the Company competes are es…

Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm Revenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal 2017, the last full year before acquisition, to an annualized run-rate of over $60 million; ~330% growth at a CAGR of approximately 18% Successive record revenue years in 2023, 2024 and 2025, with 2026 expected to continue the trend, based on distribution volumes and performance to date Pharmacies …

Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreements Gross margins of over 90% - among the highest-margin revenue streams in the Company, with raw materials largely supplied by clients Record production pipeline of more than 32.7 million units, up approximately sixfold since mid-2024 and close to threefold since the start of this year, with 7.7 mil…

Community Health Systems (NYSE: CYH - Get Free Report) and Cosmos Health (NASDAQ: COSM - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership. Valuation and Earnings This table compares

7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today Secured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target Pharma Coverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026 Agreements extending up to ten years provide long-term visibility on production …

Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets. CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption Intellectual property owned outright, with patent appl…

500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio Cumulative contract manufacturing orderbook increases to more than 27.5 million units, up from over 25 million units reported in June 2026 Further streng…

First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet Formulated for dogs, cats, horses, companion and large animals, and supplied in a 500ml pump-dispenser bottle Sales have commenced in the United Kingdom, with additional European markets to follow from Q4 2026 Multichannel strategy initially focused on e-commerce, with planned expansion into pet store chains and veterinary clinics Certified under European standards EN 165…

A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M.

$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floor Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost contr…

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories.

Cosmos Health Enters Saudi Arabia. Signs Exclusive Distribution Agreement With Innova Healthcare; Secures Purchase Order of 126,000 Sky Premium Life Units.

Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 million Continued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8% Demonstrated operating leverage and disciplined inventory management, with Q2 oper…